MUMBAI (Reuters) - Shares in Sun Pharmaceutical Industries
Analysts say results warning can cut FY16 consensus earnings estimates by 8-10 percent as company struggles to fix manufacturing problems at Ranbaxy Laboratories
(Reporting by Abhishek Vishnoi; Editing by Gopakumar Warrier)